KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inovio Pharmaceuticals (INO) EBITDA (2016 - 2025)

Historic EBITDA for Inovio Pharmaceuticals (INO) over the last 17 years, with Q3 2025 value amounting to -$21.2 million.

  • Inovio Pharmaceuticals' EBITDA rose 2244.09% to -$21.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$89.7 million, marking a year-over-year increase of 2487.63%. This contributed to the annual value of -$112.4 million for FY2024, which is 2191.27% up from last year.
  • Latest data reveals that Inovio Pharmaceuticals reported EBITDA of -$21.2 million as of Q3 2025, which was up 2244.09% from -$23.1 million recorded in Q2 2025.
  • Over the past 5 years, Inovio Pharmaceuticals' EBITDA peaked at -$20.4 million during Q4 2024, and registered a low of -$105.5 million during Q4 2021.
  • Moreover, its 5-year median value for EBITDA was -$35.8 million (2022), whereas its average is -$47.1 million.
  • Its EBITDA has fluctuated over the past 5 years, first crashed by 25961.27% in 2021, then skyrocketed by 6443.05% in 2023.
  • Inovio Pharmaceuticals' EBITDA (Quarter) stood at -$105.5 million in 2021, then soared by 46.97% to -$55.9 million in 2022, then soared by 51.04% to -$27.4 million in 2023, then increased by 25.64% to -$20.4 million in 2024, then fell by 4.13% to -$21.2 million in 2025.
  • Its EBITDA stands at -$21.2 million for Q3 2025, versus -$23.1 million for Q2 2025 and -$25.1 million for Q1 2025.